Skip to main content
. Author manuscript; available in PMC: 2019 May 31.
Published in final edited form as: Stem Cell Res. 2019 Feb 1;35:101401. doi: 10.1016/j.scr.2019.101401

Fig. 2.

Fig. 2

iPSC-MSC administration, in vivo, reduces cytokine production and weight loss in mice with GvHD. The percent of (A) human CD45 (B) human CD4 and (C) human CD8 positive PBMCs, was determined by flow cytometric analysis of peripheral blood samples from single- (n = 8) and dual-dose control (n = 8), GvHD control (n = 12), single- (n = 12) and dual-dose-treated mice (n = 12) harvested on day +19 after disease induction. (D) Circulating IFNγ was measured for cohorts of mice described in A, using standard ELISA techniques. (E) The percent weight change for cohorts of mice described in A was also determined. Data are the mean + SEM. *P ≤.05, **P < .01, ***P < .001; unpaired Student’s t-test.